Ratings Thermo Fisher Scientific Inc. Deutsche Boerse AG

Equities

TN80

CA88355G1000

Delayed Deutsche Boerse AG Other stock markets 09:29:01 2024-05-28 EDT			5-day change	1st Jan Change
13.9 ^EUR	-0.71%		-2.11%	0.00%

05-24	Declaration of Voting Results by Thermo Fisher Scientific Inc	CI
05-22	Thermo Fisher Scientific Keeps Quarterly Dividend of $0.39 a Share, Payable July 15 to Shareholders of Record on June 14	MT

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company is in debt and has limited leeway for investment
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.68 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC INC.	0.00%	223B	-
DANAHER CORPORATION	+11.25%	195B	B-
INTUITIVE SURGICAL, INC.	+18.51%	144B	B-
BOSTON SCIENTIFIC CORPORATION	+29.61%	111B	A-
SIEMENS HEALTHINEERS AG	+2.32%	65.19B	A-
EDWARDS LIFESCIENCES CORPORATION	+13.70%	53.02B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	50.28B	B+
AGILENT TECHNOLOGIES, INC.	+6.44%	44.15B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.66%	36.45B	-
RESMED, INC.	+19.98%	31.33B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes